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Selenium and iodine supplementation of rural Tibetan children
affected by Kashin-Beck osteoarthropathy1–3
Rodrigo Moreno-Reyes, Françoise Mathieu, Marleen Boelaert, Françoise Begaux, Carl Suetens, Maria T Rivera, Jean Nève,
Noémi Perlmutter, and Jean Vanderpas
ABSTRACT
Background: Kashin-Beck disease is an osteoarthropathy endemic
in selenium- and iodine-deficient areas around Lhasa, Tibet.
Objective:We assessed the efficacy of selenium supplementation
on disease progression.
Design: A double-blind, randomized controlled trial of selenium
supplementation was carried out in 324 children aged 5–15 y who
had Kashin-Beck disease. Two hundred eighty children received
iodized oil before being randomly assigned to receive selenium
or placebo, and a control group of 44 subjects was not supple-
mented at all. Clinical and radiologic signs, selenium status, uri-
nary iodine, and thyroid function were evaluated at baseline and
at 12 mo.
Results: The frequencies of joint pain, decreased joint mobility,
and radiologic abnormalities were not significantly different
between the 3 groups at 12 mo. Height-for-age z scores increased
significantly in the subjects who received placebo and iodine or
selenium and iodine. In contrast, unsupplemented control subjects
did not recover from growth retardation. Serum selenium con-
centrations at 12 mo were within the reference range and were
significantly greater in the selenium-iodine group than in the
placebo-iodine group. Serum thyroid hormone concentrations
were within the reference ranges after the administration of
iodine, and these values were not significantly affected by sele-
nium supplementation.
Conclusions: The results of this study do not rule out the possi-
bility that selenium may help to prevent the occurrence of Kashin-
Beck disease. However, selenium supplementation had no effect
on established Kashin-Beck disease, growth, or thyroid function
once iodine deficiency was corrected. These results suggest that
iodine, but not selenium, deficiency should be corrected in
Tibetan children with Kashin-Beck disease. Am J Clin Nutr
2003;78:137–44.
KEY WORDS Selenium, iodine, Kashin-Beck disease,
osteoarthropathy, Tibet
INTRODUCTION
Kashin-Beck disease is an osteoarthropathy endemic in certain
areas of China, Siberia, and North Korea that causes joint defor-
mation and limited joint mobility (1, 2). The most severe cases
of the disease result in decreased limb length and short stature.
Selenium deficiency has been suggested as a risk factor because
the disease is limited to low-selenium areas (3, 4). However, the
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efficacy of selenium in the prevention of Kashin-Beck disease is
controversial (4). In a cross-sectional community survey in Tibet,
we found no association between individual selenium status and
Kashin-Beck disease, whereas iodine deficiency was a risk factor
(5). Although the Tibetan health authorities recommend iodiza-
tion of salt, there is evidence that this recommendation is rarely
put into practice in remote communities. In our baseline study,
we found extremely low urinary iodine concentrations in almost
all the study subjects, ie, children with or without Kashin-Beck
disease (5). Other risk factors for Kashin-Beck disease, such as
fungal contamination, have also been suggested (6). Tibetan
health authorities have advocated selenium supplementation, but
the supplementation program is not strictly adhered to. When
Médecins sans Frontières started a health program in the area in
1992, there was little scientific evidence to support large-scale
preventive selenium supplementation. Because the huge num-
bers of Kashin-Beck cases were of more immediate concern,
Médecins sans Frontières decided to launch a physiotherapy pro-
gram. In addition, the hypothesis was raised that if selenium defi-
ciency was supposedly a contributing factor to the onset of the
disease, selenium supplementation might possibly reduce the
osteoarticular damage or correct growth retardation in persons
with the disease. In this double-blind, randomized controlled
trial, we evaluated the effect of 12 mo of selenium supplementa-
tion in combination with iodine on clinical symptoms and signs,
thyroid metabolism, and growth in Tibetan subjects with Kashin-
Beck disease. Because selenium supplementation in iodine-deﬁcient
subjects can aggravate a status of hypothyroidism (7), we first
corrected iodine deficiency before randomly assigning study sub-
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FIGURE 1. Male, 16-y-old Tibetan adolescent with Kashin-Beck dis-
ease. The picture shows some of the signs of severe Kashin-Beck disease
(stage III), with bilateral shortening and deformation of the distal ends of
the humerus. The adolescent (height 1.45 m) was smaller than healthy
Tibetan adolescents of the same age, although he was not dwarfed. The
hands and joints of the lower limbs were affected.
SUBJECTS AND METHODS
Study subjects
The study area was situated in Lhasa prefecture, Tibet, where
12 villages with known Kashin-Beck disease occurrence were
selected. The villages had a median population size of 143 inhab-
itants (quartile 1: 125; quartile 3: 185). Only subjects aged 5–15 y
who were affected by Kashin-Beck disease were eligible for the
study. Two members of the study team visited each household in
the villages and invited all subjects aged 5–15 y to report to the
health center. The age-specific prevalence rate of Kashin-Beck
disease for children aged 5–15 y ranged from 13% to 100%
(median: 56%) (5). Kashin-Beck disease was diagnosed when a
child had persistent pain, restricted mobility, or deformity of the
knees, ankles, elbows, wrist, interphalangeal joints, hips, or shoul-
ders, as shown by physical examination, in the absence of local
inflammation or history of trauma (8). An intramuscular injection
of 1 mL iodized oil (Lipiodol, 475 mg I/mL; Guerbet, Aulnay-
sous-bois, France) was given to subjects 4 mo before the selenium
supplementation. Subsequently, subjects affected by Kashin-Beck
disease were randomly and double-blindly assigned either to
placebo (placebo-iodine group) or selenium (selenium-iodine
group) supplementation. If several persons with Kashin-Beck dis-
ease were found within the same household, they were block-
assigned to either the placebo-iodine group or the selenium-iodine
group to avoid contamination. A group of 44 children with
Kashin-Beck disease was recruited in a separate village to act as
a control group. These children were not supplemented with
iodine or selenium during the study. The evolution of Kashin-Beck
disease and growth patterns were studied in this group to control
for any environmental or nutritional trend. All of these children
received iodine supplementation at the end of the study period.
The study protocol was approved by the Lhasa Health Bureau of
Tibet and by the institutional review board of the Ambroise Paré
Hospital of Mons, Belgium. Enrollment in the study was condi-
tional on informed consent from the caretaker. The present study
was conducted from May 1995 through November 1996.
Intervention
The selenium-iodine group received 100  g Se/d and 1 mg Se/wk
in the form of sodium selenate tablets (Laboratoria Wolfs,
Antwerp, Belgium) for 11 mo. The placebo-iodine group received
tablets having an appearance identical to that of the selenate
tablets but containing no active substance. During the 12th month,
both groups received only the weekly 1-mg selenate or placebo
tablets because the supply of 100- g tablets was interrupted as a
result of logistical problems.
The dosing schedule described above was an adaptation to the
very difficult field conditions in Tibet and was aimed at effective
supplementation in the intervention group. Direct supervision by
study investigators of daily tablet intake was not possible because
most of the study villages were very remote from Lhasa. There-
fore, the community health worker of the village was instructed
to give a daily dose of 100  g Se or placebo to the study subjects.
The investigators visited the villages once a week and gave a tablet
containing 1 mg Se or placebo to each of the study subjects, who
ingested it under direct observation.
Clinical examination
All children were interviewed with a standardized questionnaire
and examined by a physiotherapist, who was blinded to the study
group, at the start and at 12 mo of selenium supplementation.
Work ability, joint pain during the past 24 h, and morning joint
stiffness were recorded for every subject in the 2 intervention
groups. The patients’disease was classified into 3 stages accord-
ing to the presence of at least one enlarged joint, pain, degree of
limitation, and the following associated symptoms: tiredness,
muscle weakness, ability to work, flat feet, waddling gait, and
dwarfism (Figure 1; 8).
The main endpoint of the study, clinical improvement, was
defined as an improvement of at least one stage on the scale of
clinical severity. A height-for-age, height-for-weight, and
weight-for-age index was calculated for each subject on the basis
of reference tables from the National Center for Health Statistics,
the Centers for Disease Control and Prevention, and the World
Health Organization (9).
Laboratory measurements
Blood samples were collected for measurement of serum selenium,
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FIGURE 2. Trial profile.
thyrotropin, and thyroxine-binding globulin. Urine samples
were collected for measurement of selenium and iodine and to
monitor iodine status and compliance with selenium supple-
mentation. Serum selenium was measured by atomic absorp-
tion spectrometry with Zeeman background correction (Perkin-
Elmer Z3030; Perkin-Elmer, Uberlingen, Germany) (10).
GPX was measured spectrophotometrically on a biochemical
analyzer (Hitachi 717; Boehringer-Mannheim, Mannheim,
Germany) as previously described (5). Serum thyroxine, tri-
iodothyronine, and thyrotropin were measured by chemilumi-
nescence detection (ACS 180; Corning, Los Angeles). Serum
thyroxine-binding globulin was measured by radioimmunoas-
say with commercial kits (Biocode, Liège, Belgium). Urinary
iodine was measured by using a Technicon Autoanalyzer (Tech-
nicon, Tarrytown, NY) (5). Urine selenium was measured by
fluorimetry (luminescence spectrophotometer LS50B; Perkin-
Elmer) after reaction with 2,3-diaminonaphthalene (11). The
reference ranges for healthy adults in Belgium were as follows:
thyroxine, 77–154 nmol/L; triiodothyronine, 1.2–3.0 nmol/L;
thyrotropin, 0.3–4.6 mU/L; serum selenium, 60–105  g/L;
GPX, 550–1100 U/L; urinary iodine, 50–250  g/L; and urinary
selenium, 10–50  g/L.
Radiologic evaluation
Radiographs of the right hand and foot were taken at the
start of selenium supplementation and after 12 mo. A pediatric
radiologist, who was blinded to the subjects’study group, rated
the films. Skeletal maturity was assessed according to Greulich
and Pyle (12). Skeletal delay was calculated as chronologic age
minus radiologic bone age. A radiologic diagnosis of Kashin-
Beck disease was made if the subject had at least one of the
following signs: irregular erosion of carpal or tarsal bones,
irregular metaphyseal widening, irregular erosions of the
metacarpal or metatarsal bones and phalanges, cone-shaped
epiphyses of phalanges, fragmentation of the cone-shaped epi-
physis, premature closure of the metaphysis with subsequent
shortening of the metacarpal or metatarsal bone and phalanges,
or talus collapse with bone densification. Radiologic improve-
ment was defined as regression or disappearance of existing
lesions by comparing films taken before and after selenium
supplementation.
Statistical analysis
For serum thyrotropin, selenium, GPX, and urinary iodine,
the geometric mean was computed because the log-transformed
values fitted a normal distribution better than the untrans-
formed values did. Differences between independent means
were tested by one-factor analysis of variance, and the
Scheffe multiple comparison test was used to compare pairs
of means. For paired samples, a paired t test was used. Dif-
ferences between proportions were tested by chi-square tests.
All P values were two sided. A two-factor repeated-measures
analysis of variance was performed, with time as the within-
factor variable and treatment as the between-factor variable,
to compare the effects of time and treatment and time-by-
treatment interactions for weight-for-height, weight-for-age,
and height-for-age z scores; urinary iodine and selenium; and
serum thyroxine, triiodothyronine, and thyrotropin. If the
interaction was significant, t tests between groups were done
and adjusted for multiple comparisons (Bonferroni correc-
tion). The statistical analyses were performed with SPSS for
WINDOWS, release 10.0.5 (SPSS Inc, Chicago).
RESULTS
Subjects and baseline characteristics
Among the 324 subjects with Kashin-Beck disease who were
recruited, 280 received iodine. Because the caretakers of 72
subjects did not give consent, only 208 subjects were included
in the supplementation trial. Forty-four subjects were not sup-
plemented with selenium or iodized oil (Figure 2). The char-
acteristics of the unsupplemented group, the placebo-iodine
group, and the selenium-iodine group at baseline, ie, 4 mo after
iodine supplementation and before the start of selenium or
placebo supplementation, are shown in Table 1. Skeletal
delays, height-for-age z scores, clinical severities, and fre-
quencies of radiologic abnormalities were not significantly dif-
ferent between the 3 groups. The unsupplemented group had
significantly lower serum thyroxine concentrations and signi-
ficantly higher serum triiodothyronine and thyrotropin con-
centrations than did the iodine-supplemented groups. Serum
thyroxine, triiodothyronine, and thyrotropin concentrations
were within the reference ranges in the 2 iodine-supplemented
groups. The mean urinary iodine concentration in the unsup-
plemented group was below the reference range (50–250  g/L),
but the mean concentrations in the 2 iodine-supplemented
groups were within the reference range. Serum selenium con-
centrations and serum GPX were very low and did not differ
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TABLE 1
Baseline characteristics of unsupplemented subjects with Kashin-Beck disease and of iodine-supplemented subjects with Kashin-Beck disease who were
assigned to receive placebo or selenium1
Characteristic Unsupplemented Placebo and iodine Selenium and iodine P2
Age (y) 10 ± 0.53 [44]4 10 ± 0.3 [95] 10 ± 0.28 [113] 0.79
Sex, male [n (%)] 17 (39) 61 (64) 72 (64) 0.0085
Weight (kg) 23.9 ± 1.1 [44] 26.8 ± 0.8 [95] 26.6 ± 0.7 [113] 0.10
Height (cm) 119 ± 2.2 [44] 122 ± 1.5 [95] 121 ± 1.4 [113] 0.61
Skeletal delay (y) 2.7 ± 0.3 [41] 2.8 ± 0.1 [93] 2.9 ± 0.1 [104] 0.67
Height-for-age z score  3.1 ± 0.1 [44]  3.0 ± 0.1 [95]  3.2 ± 0.1 [113] 0.42
Scale of clinical severity [n (%)]
Stage I 34 (77) 79 (83) 95 (84) 0.84
Stage II or III 10 (23) 16 (17) 18 (16) 0.84
Radiologic abnormalities [n (%)] 7 (18) 11 (12) 16 (14) 0.65
Serum T4 (nmol/L) 81 ± 5 [39] 97 ± 3 [80] 107 ± 3 [92] <0.001
Serum T3 (nmol/L) 2.3 ± 0.1 [39] 1.9 ± 0.03 [79] 2.1 ± 0.03 [93] <0.001
Serum TBG (mg/L) 18.5 ± 0.7 [41] 18.3 ± 0.6 [77] 19.1 ± 0.5 [89] 0.55
Serum TSH (mU/L)
Geometric x – 5.5 [41] 2.9 [84] 2.6 [99] <0.0015
Limits6 4.6–6.6 2.7–3.1 2.4–2.8
Urinary iodine ( g/L)
Geometric x – 11 [37] 202 [67] 216 [83] <0.0015
Limits6 9–13 180–227 192–244
Serum selenium ( g/L)
Geometric x – 13.4 [42] 14.1 [67] 13.8 [86] 0.77
Limits6 12.6–14.3 13.5–14.7 13.3–14.4
Serum GPX (U/L)
Geometric x – 200 [41] 226 [88] 220 [100] 0.59
Limits6 181–221 212–239 205–235
1T4, thyroxine; T3, triiodothyronine; TBG, thyroxine-binding globulin; TSH, thyroid-stimulating hormone; GPX, glutathione peroxidase activity.
2One-way ANOVA or chi-square test. The Scheffe multiple comparison test was used to compare pairs of means.
3x – ± SE.
4n in brackets.
5Unsupplemented subjects compared with placebo- and iodine-supplemented subjects and selenium and iodine-supplemented subjects.
6Values 1 SE below and 1 SE above the mean on the logarithmic scale.
Clinical and radiologic outcomes
Clinical outcomes after 12 mo in the unsupplemented,
placebo-iodine, and selenium-iodine groups are shown in
Table 2. Frequencies of joint pain, decreased joint mobility, and
morning joint stiffness did not differ significantly between the
placebo-iodine group and the selenium-iodine group. The number
of subjects with morning joint stiffness was significantly higher
in the unsupplemented group than in the selenium-iodine group.
Radiologic improvement was poor and did not differ significantly
between the 3 groups. Three subjects, all belonging to the
placebo-iodine group, showed new radiologic lesions at follow-
up; however, comparison with the selenium-iodine group was not
significant (3 of 71 in the placebo-iodine group compared with 0
of 90 in the selenium-iodine group; P = 0.08, Fisher exact test).
TABLE 2
Clinical outcomes after 12 mo in unsupplemented subjects with Kashin-Beck disease and in iodine-supplemented subjects with Kashin-Beck disease who
were assigned to receive placebo or selenium
Characteristic Unsupplemented Placebo and iodine Selenium and iodine P1
Weight (kg) 24.7 ± 1.22 [41]3 27.2 ± 0.9 [88] 27.3 ± 0.8 [108] 0.22
Height (cm) 124 ± 2 [41] 128 ± 2 [88] 129 ± 1 [108] 0.20
Skeletal delay (y) 2.9 ± 0.3 [39] 2.8 ± 0.1 [84] 2.9 ± 0.1 [104] 0.76
Joint pain during the past 24 h [n (%)] 6 (15) 13 (15) 21 (19) 0.63
Decreased joint mobility [n (%)] 7 (17) 16 (18) 25 (23) 0.50
Morning joint stiffness [n (%)] 7 (17) 6 (7) 4 (4) 0.0184
Scale of clinical severity [n (%)]
Stage I 34 (83) 74 (84) 85 (79) 0.83
Stage II or III 7 (17) 14 (16) 23 (21) 0.83
Clinical improvement [n (%)] 1 (2) 4 (5) 7 (7) 0.46
Radiologic improvement [n (%)] 0 (0) 0 (0) 1 (0.1) 1
1One-way ANOVA or chi-square test. The Scheffe multiple comparison test was used to compare pairs of means.
2x – ± SE.
3n in brackets.
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FIGURE 3. Mean (±SE) weight-for-height, weight-for-age, and height-
for-age z scores before and after 12 mo of selenium supplementation in
unsupplemented subjects ( ), placebo-iodine–supplemented subjects ( ),
and selenium-iodine–supplemented subjects ( ). In two-factor repeated-
measures ANOVA, the main effect of time was significant (P < 0.001), as
was the time   iodine interaction (weight-for-height z score, P < 0.001;
weight-for-age z score, P = 0.026; height-for-age z score, P = 0.001).
*Significantly different from the baseline value, P < 0.001.
FIGURE 4. Mean urinary iodine concentrations in the placebo-iodine–sup-
plemented subjects ( ) and the selenium-iodine–supplemented subjects ( )
from 4 mo before to 12 mo after selenium supplementation. The reference
range for urinary iodine concentrations is located above the dotted line. There
was a signiﬁcant main effect of time (P < 0.001). *Signiﬁcantly different from
all subsequent values, P < 0.001 (Helmert contrast).
Weight-for-height, weight-for-age, and height-for-age z scores in
the 3 groups before and after the 12-mo supplementation period are
shown in Figure 3. The placebo-iodine– and selenium-iodine–
supplemented children showed a significant increase in height-
for-age z score, but the unsupplemented children did not. Weight-
for-height and weight-for-age z scores decreased significantly in
the 3 groups, suggesting that linear growth in the placebo-iodine–
and selenium-iodine–supplemented children was not accompanied
by appropriate weight gain.
Iodine and selenium status
The urinary iodine concentrations observed in the placebo-
iodine and selenium-iodine groups are shown in Figure 4. Before
iodine supplementation, the urinary iodine concentrations were
 12  g/L in both groups. These values increased significantly
after iodine and remained within the reference range (50–250  g/L)
throughout most of the study period. However, 16 mo after iodine
supplementation, they had fallen below 50  g/L (ie, 39  g/L in
both groups).
Serum concentrations of thyroid hormones and thyrotropin
in the placebo-iodine and selenium-iodine groups are shown in
Figure 5. Serum thyroxine concentrations increased significantly
4 mo after iodine supplementation, and the concentrations were
even higher at the end of the study in both groups. Serum tri-
iodothyronine concentrations followed a pattern that mirrored that
of serum thyroxine concentrations. Serum triiodothyronine con-
centrations decreased significantly 4 mo after iodine supplemen-
tation but increased again to preiodine concentrations at the end of
the study in both groups. Serum thyrotropin concentrations, which
were  6 mU/L before iodine supplementation, decreased signifi-
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FIGURE 6. Mean (±SE on the logarithmic scale) urinary selenium
concentrations in the placebo-iodine–supplemented subjects ( ) and the
selenium-iodine–supplemented subjects ( ) during 12 mo of placebo or
selenium supplementation. There was a significant main effect of time (P
< 0.001) and a significant time   treatment interaction (P < 0.001). *Signi-
ficantly different from placebo-iodine–supplemented subjects, P < 0.0125
(t test with Bonferroni correction).
FIGURE 5. Mean (±SE) serum thyroxine (T4), triiodothyronine (T3),
and thyrotropin (thyroid-stimulating hormone, TSH) concentrations in the
placebo-iodine–supplemented subjects ( ) and the selenium-iodine–
supplemented subjects ( ) from 4 mo before to 12 mo after selenium sup-
plementation. The reference range for serum TSH concentrations is within
the 2 dotted lines. For serum TSH, the values are means ± SEs on the log-
arithmic scale. A significant main effect of time was observed for serum
T4 (P < 0.001), T3 (P < 0.001), and TSH (P = 0.011). *Significantly dif-
ferent from all subsequent values, P < 0.001 (Helmert contrast). For serum
T3, there was a significant main effect of group (P = 0.03).
groups. Serum thyrotropin concentrations remained within the
normal range during the 12-mo supplementation period in both
groups but were significantly lower at the end of the supplemen-
tation period than at the beginning (Figure 5, bottom panel).
Serum thyrotropin was not significantly affected by selenium sup-
plementation for 12 mo. Four subjects had low serum thyrotropin
concentrations (<0.3 mU/L) 4 mo after iodine supplementation.
Serum thyrotropin concentrations were normal at 12 mo in the 2 sub-
jects who accepted blood testing. Compliance with selenium
supplementation was monitored by measuring urinary selenium
concentrations at regular intervals (Figure 6). Urinary sele-
nium concentrations increased 30-fold in the selenium-iodine
group and 4-fold in the placebo-iodine group. After 12 mo of sup-
plementation, mean serum selenium concentrations were within
the reference range and were significantly greater in the selenium-
iodine group than in the placebo-iodine group [61  g/L (range:
43–85  g/L; n = 40) compared with 29  g/L (range: 17–50  g/L;
n = 39); P < 0.001]. Mean serum GPX was also significantly
greater in the selenium-iodine group than in the placebo- iodine
group [818 U/L (range: 629–1064 U/L; n = 44) compared with 442
U/L (range: 269–726 U/L; n = 38 subjects); P < 0.001]. The rela-
tions between individual values for serum selenium and GPX after
selenium supplementation are shown in Figure 7. Most of the sub-
jects in the selenium-iodine group had values for serum selenium
and GPX within the respective reference ranges, whereas all but 2
of the subjects in the placebo-iodine group and all of the subjects
in the unsupplemented group were below the reference ranges.
DISCUSSION
Selenium and iodine deficiency are endemic in Tibet (5).
















































 KASHIN-BECK OSTEOARTHROPATHY 143
FIGURE 7. Relation between serum glutathione peroxidase activity
(GPX) and serum selenium concentration after selenium supplementa-
tion in unsupplemented subjects ( ), placebo-iodine–supplemented sub-
jects ( ), and selenium-iodine–supplemented subjects ( ). Serum sele-
nium and GPX were significantly correlated for serum selenium
concentrations <60  g/L (r = 0.77, P < 0.001) but not for concentrations
>60  g/L (r = 0.05, P = 0.81). There were significant correlations
between serum selenium and GPX in the unsupplemented subjects (r = 0.82,
P < 0.001), the placebo-iodine–supplemented subjects (r = 0.83,
P < 0.001), and the selenium-iodine–supplemented subjects (r = 0.34,
P = 0.04). The dotted lines indicate the lower reference value for serum
selenium concentrations and GPX.
cretinism, the effect of selenium deficiency on health remains
uncertain, particularly in relation to Kashin-Beck disease. Because
selenium supplementation was shown to prevent Keshan disease,
a cardiomyopathy endemic in selenium-deficient areas of China,
it was proposed that Kashin-Beck disease might also be related to
low selenium status (4). The present study differs in several ways
from previous studies (13, 14): it was designed as a double-blind,
randomized controlled trial; the criteria for inclusion in the trial
were standardized; and, because selenium may aggravate hypothy-
roidism in selenium- and iodine-deficient subjects, iodine defi-
ciency was first corrected (7). Previously performed trials in China
included only subjects with radiologic lesions, but only 14% of
the subjects who met the clinical criteria for Kashin-Beck disease
in the present study showed radiologic lesions. Persons with radi-
ologic lesions have more advanced stages of the disease and are
expected to be less influenced by selenium treatment than are per-
sons without radiologic lesions. In the present study, 12 mo of
selenium supplementation of subjects affected by Kashin-Beck
disease had no effect on the main symptoms and signs, ie, joint
pain and decreased joint mobility. The study does not exclude the
possibility that selenium may prevent the occurrence of Kashin-
Beck disease in unaffected children from endemic areas or the
occurrence of new lesions in affected children, because new radi-
ologic lesions occurred in the placebo-iodine group only. Growth
retardation diminished significantly in both the placebo-iodine
group and the selenium-iodine group but not in the unsupple-
mented group, and this effect was probably due to the correction
of iodine deficiency. Selenium supplementation had no additional
effect on stunting once iodine deficiency was corrected. Interest-
ingly, the improved growth in the iodine-supplemented children
was not accompanied by an increase in body weight. Study sub-
jects in the 3 groups had lower weight-for-height and weight-for-
age z scores after the 12-mo supplementation period. This proba-
bly reflects a decrease in food availability in the region, because
the unsupplemented group showed a similar pattern (15). The cor-
rection of iodine deficiency thus appeared to stimulate growth in
children affected by Kashin-Beck disease, notwithstanding a sit-
uation of overall food scarcity. This study shows that a single dose
of 475 mg I could correct severe iodine deficiency in iodine- and
selenium-deficient subjects for up to 1 y. Sixteen months after
iodine administration, serum thyroxine and thyrotropin concen-
trations were within their respective reference ranges, despite the
fact that urinary iodine concentrations were below the reference
range. Four subjects had transient biochemical hyperthyroidism.
This adverse reaction cannot be completely avoided after iodine
supplementation, but the incidence should be reduced by admin-
istering low doses of iodine and by avoiding iodine treatment of
subjects with large nodular goiter. In any case, the adverse effects
of a transient iodine-induced hyperthyroidism must be balanced
against the risk of long-standing hypothyroidism due to uncor-
rected iodine deficiency, particularly in children and pregnant
women (16, 17).
After 12 mo of selenium supplementation, serum selenium con-
centrations in the selenium-iodine group were within the reference
range and were significantly greater than those in the placebo-iodine
group. The monitoring of compliance allowed us to detect a mod-
erate increase in urinary selenium concentrations in the placebo-
iodine group.The source of this increase is unclear, but some of the
subjects in the placebo-iodine group may have received selenium
tablets from the Tibetan health authorities. Recycling of excreted
selenium, similar to the recycling of iodine observed in Nepal,
where living conditions are similar, may also have contributed to
this result (18). Urinary selenium excretion increased 30-fold from
the baseline values, and serum selenium concentrations were within
the reference range in the selenium-iodine group. The observed
relation between serum selenium and GPX substantiates the bio-
logical efﬁciency of selenium treatment. The strong correlation
between these 2 variables in the unsupplemented and placebo-iodine–
supplemented subjects (Figure 7) reflects the inadequacy of their
seleniumstatus.Incontrast,theweakcorrelationintheselenium-iodine–
supplemented subjects shows the successful correction of defi-
ciency, as shown by the sufficiency of selenium status for satisfac-
tion of GPX in serum (19). Therefore, we estimated that the appar-
ent introduction of some exogenous selenium into the community
during the study did not preclude a valid comparison.
The effects of selenium supplementation on thyroid hormone
metabolism have been studied extensively in selenium-deficient
animals (20–25), but few studies are available on the effects of
low selenium status on thyroid hormone metabolism in humans
(26–28). Our data show that after 12 mo of selenium supplemen-
tation, there were no significant differences in serum concentra-
tions of thyroid hormones and thyrotropin between the placebo-
iodine and selenium-iodine groups. This finding supports the
findings of previous studies that suggest a moderate effect of sele-
nium deficiency on thyroid hormones (27, 29). The thyroid gland,
















































 144 MORENO-REYES ET AL
activities in these tissues are maintained (30). This might explain
the negligible effect of selenium deficiency on thyroid hormone
metabolism. In conclusion, selenium supplementation had no
effect on growth or thyroid function in patients with Kashin-Beck
disease once iodine deficiency was corrected. The present data do
not support the use of selenium supplementation for the treatment
of subjects with Kashin-Beck disease. Therefore, iodine but not
selenium deficiency should be corrected in Tibetan children with
Kashin-Beck disease.
We are indebted to Médecins Sans Frontières in Tibet and Brussels for its
continuous support.
The study was designed by RM-R, CS, and FM. Data were collected by RM-
R, CS, FM, JV, and FB. MTR and JN did the laboratory assessments. NP under-
took the radiologic evaluations. RM-R, CS, MB, and JV participated in the data
analysis. All authors participated in writing and revising the report. None of
the authors had any conflicts of interest.
REFERENCES
1. Sokoloff L. The history of Kashin-Beck disease. N Y State J Med
1989;89:343–51. (Published erratum appears in N Y State J Med
1989;89:486.)
2. Allander E. Kashin-Beck disease. An analysis of research and public
health activities based on a bibliography 1849–1992. Scand J
Rheumatol Suppl 1994;99:1–36.
3. Wu J, Xu GL. Plasma selenium content, platelet glutathione peroxi-
dase and superoxide dismutase activity of residents in Kashin-Beck
disease affected area in China. J Trace Elem Electrolytes Health Dis
1987;1:39–43.
4. Yang GQ, Ge KY, Chen JS, Chen XS. Selenium-related endemic dis-
eases and the daily selenium requirement of humans. World Rev Nutr
Diet 1988;55:98–152.
5. Moreno-Reyes R, Suetens C, Mathieu F, et al. Kashin-Beck
osteoarthropathy in rural Tibet in relation to selenium and iodine sta-
tus. N Engl J Med 1998;339:1112–20.
6. Chasseur C, Suetens C, Nolard N, Begaux F, Haubruge E. Fungal
contamination in barley and Kashin-Beck disease in Tibet. Lancet
1997;350:1074.
7. Contempre B, Dumont JE, Ngo B, Thilly CH, Diplock AT,Vanderpas J.
Effect of selenium supplementation in hypothyroid subjects of an
iodine and selenium deficient area: the possible danger of indiscrim-
inate supplementation of iodine-deficient subjects with selenium. J
Clin Endocrinol Metab 1991;73:213–5.
8. Mathieu F, Begaux F, Lan ZY, Suetens C, Hinsenkamp M. Clinical
manifestations of Kashin-Beck disease in Nyemo Valley, Tibet. Int
Orthop 1997;21:151–6.
9. WHO Working Group. Use and interpretation of anthropometric
indicators of nutritional status. Bull World Health Organ 1986;64:
929–41.
10. Neve J, Chamart S, Molle L. Optimization of a direct procedure for
the determination of selenium in plasma and erythrocytes using Zee-
man effect atomic absorption spectroscopy. In: Brätter P, Schramel P,
eds. Trace element-analytical chemistry in medicine and biology.
Berlin: Walter de Gruyter, 1987:349–58.
11. Wasowicz W, Zachara BA. Selenium concentrations in the blood and
urine of a healthy Polish sub-population. J Clin Chem Clin Biochem
1987;25:409–12.
12. Greulich WW, Pyle SI. Radiographic atlas of skeletal develop-
ment of hand and wrist. Stanford, CA: Stanford University Press,
1959.
13. Lian S-T, Zhang J-C, Shang X, Mu S-Z, Zhang F-J. Effects of sele-
nium supplementation in prevention and treatment of Kashin-Beck
disease. In: Combs GF, Spallholz J, Levander OA, Oldfield JE, eds.
Selenium in biology and medicine: proceedings of the Third Interna-
tional Symposium on selenium in biology and medicine, held May
27–June 1, 1984, Xiangshan (Fragrance Hills) Hotel, Beijing, Peo-
ple’s Republic of China. New York:Van Nostrand Reinhold Company,
1987:938–46.
14. Wan Z, Lu S, Jing D, Li J, Ren S, Chen D. Observations by x-ray stud-
ies on the effects of selenite supplemented salt on the prevention and
treatment of Kashin-Beck disease. In:Tan J, Peterson PJ, Li Ribang WW,
eds. Environmental life elements and health. Beijing: Science Press,
1990:356–7.
15. Harris NS, Crawford PB,Yangzom Y, Pinzo L, Gyaltsen P, Hudes M.
Nutritional and health status of Tibetan children living at high alti-
tudes. N Engl J Med 2001;344:341–7.
16. Moreno-Reyes R, Boelaert M, el Badawi S, Eltom M,Vanderpas JB.
Endemic juvenile hypothyroidism in a severe endemic goitre area of
Sudan. Clin Endocrinol (Oxf) 1993;38:19–24.
17. Vanderpas JB, Rivera VM, Bourdoux P, et al. Reversibility of severe
hypothyroidism with supplementary iodine in patients with endemic
cretinism. N Engl J Med 1986;315:791–5.
18. Ibbertson H, Gluckman P, Croxson M, Strang L. Goiter and endemic
cretinism in the Himalayas: a reassessment. In: Dunn J, Medeiros-Neto G,
eds. Endemic goiter and cretinism: continuing threats to world
health. Washington, DC: Pan American Health Organization, 1974:
129–34.
19. Neve J. New approaches to assess selenium status and requirement.
Nutr Rev 2000;58:363–9.
20. Campos-Barros A, Meinhold H, Walzog B, Behne D. Effects of sele-
nium and iodine deficiency on thyroid hormone concentrations in the
central nervous system of the rat. Eur J Endocrinol 1997;136:316–23.
21. Contempre B, Denef JF, Dumont JE, Many MC. Selenium deficiency
aggravates the necrotizing effects of a high iodide dose in iodine defi-
cient rats. Endocrinology 1993;132:1866–8.
22. Thompson KM, Haibach H, Sunde RA. Growth and plasma tri-
iodothyronine concentrations are modified by selenium deficiency
and repletion in second-generation selenium-deficient rats. J Nutr
1995;125:864–73.
23. Beckett GJ, Beddows SE, Morrice PC, Nicol F,Arthur JR. Inhibition
of hepatic deiodination of thyroxine is caused by selenium deficiency
in rats. Biochem J 1987;248:443–7.
24. Golstein J, Corvilain B, Lamy F, Paquer D, Dumont JE. Effects of a
selenium deficient diet on thyroid function of normal and perchlorate
treated rats. Acta Endocrinol (Copenh) 1988;118:495–502.
25. Chanoine JP, Safran M, Farwell AP, et al. Effects of selenium defi-
ciency on thyroid hormone economy in rats. Endocrinology 1992;
131:1787–92.
26. Vanderpas JB, Contempre B, Duale NL, et al. Iodine and selenium
deficiency associated with cretinism in northern Zaire. Am J Clin
Nutr 1990;52:1087–93.
27. Calomme MR, Vanderpas J, Francois B, et al. Effects of selenium
supplementation on thyroid hormone metabolism in phenylketonuria
subjects on a phenylalanine restricted diet. Biol Trace Elem Res 1995;
47:349–53.
28. Contempre B, Duale NL, Dumont JE, Ngo B, Diplock AT,Vanderpas
J. Effect of selenium supplementation on thyroid hormone metabo-
lism in an iodine and selenium deficient population. Clin Endocrinol
(Oxf) 1992;36:579–83.
29. St Germain DL, Galton VA. The deiodinase family of selenoproteins.
Thyroid 1997;7:655–68.
30. Behne D, Hilmert H, Scheid S, Gessner H, Elger W. Evidence for spe-
cific selenium target tissues and new biologically important seleno-
proteins. Biochim Biophys Acta 1988;966:12–21.
 
b
y
 
o
n
 
M
a
y
 
2
6
,
 
2
0
0
8
 
w
w
w
.
a
j
c
n
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 